Results 61 to 70 of about 8,503,937 (347)

Chemokines and Cardiovascular Risk [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2008
Based on the importance of inflammation in atherogenesis, recent work has focused on whether plasma markers of inflammation can noninvasively diagnose and prognosticate atherosclerotic disorders. Although several studies support an important pathogenic role of chemokines in atherosclerosis, potentially representing attractive therapeutic targets in ...
Lars Gullestad, Erik Øie, Kari Otterdal, Arne Yndestad, Thor Ueland, Jan Kristian Damås, Pål Aukrust, Bente Halvorsen   +7 more
openaire   +3 more sources

Evolutionary interplay between viruses and R‐loops

FEBS Letters, EarlyView.
Viruses interact with specialized nucleic acid structures called R‐loops to influence host transcription, epigenetic states, latency, and immune evasion. This Perspective examines the roles of R‐loops in viral replication, integration, and silencing, and how viruses co‐opt or avoid these structures.
Zsolt Karányi, Zita Képes, Zoltán Szabó, Eszter Csoma, Lóránt Székvölgyi   +4 more
wiley   +1 more source

Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.

New England Journal of Medicine, 2013
BACKGROUND Recent studies in animals have shown a mechanistic link between intestinal microbial metabolism of the choline moiety in dietary phosphatidylcholine (lecithin) and coronary artery disease through the production of a proatherosclerotic ...
W. Tang, Zeneng Wang, B. Levison, Robert A. Koeth, Earl B. Britt, Xiaoming Fu, Yuping Wu, S. Hazen   +7 more
semanticscholar   +1 more source

Circulating histones as clinical biomarkers in critically ill conditions

FEBS Letters, EarlyView.
Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez, Juan Carlos Ruiz‐Rodríguez, Ricard Ferrer, Raquel Durá, Antonio Artigas, Iván Bajaña, David Bolado López de Andujar, Irene Cánovas‐Cervera, Adrián Ceccato, Luis Chiscano‐Camón, Elena Climent‐Martinez, Georgia García Fernández, Gemma Goma, Verónica Monforte, Beatriz Quevedo‐Sánchez, Adolf Ruiz‐Sanmartín, Antonio Sierra‐Rivera, Nieves Carbonell Monleón   +17 more
wiley   +1 more source

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Circulation, 2019
Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration.
M. O’Donoghue, S. Fazio, R. Giugliano, Erik S. G. Stroes, Estella Kanevsky, I. Gouni-Berthold, K. Im, Armando Lira Pineda, S. Wasserman, R. Češka, M. Ezhov, J. Jukema, Henrik K. Jensen, S. Lale Tokgözoğlu, F. Mach, K. Huber, P. S. Sever, A. Keech, T. Pedersen, M. Sabatine   +19 more
semanticscholar   +1 more source

Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors

Molecular Oncology, EarlyView.
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi, Janelle‐Cheri Millen, Romela Irene Ramos, Jennifer A. Linehan, Timothy G. Wilson, Dave S. B. Hoon, Matias A. Bustos   +6 more
wiley   +1 more source

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

Molecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source

Cardiovascular risk factors, global cardiovascular risk, and vascular age in a cohort of Peruvian HIV patients

HIV & AIDS Review. International Journal of HIV-Related Problems
Introduction Data on cardiovascular risk and vascular age in patients with human immunodeficiency virus (HIV) from developing countries are scarce. Therefore, the current study aimed to determine the prevalence of cardiovascular risk factors, global ...
German Valenzuela-Rodriguez, Jaime A. Collins, Raul Castillo, Luis R. Illescas, Adrian V. Hernandez, Carlos Diaz-Arocutipa   +5 more
doaj   +1 more source

Lipid lowering with inclisiran: a real-world single-centre experience

Open Heart, 2022
Objective The reduction in circulating low-density lipoprotein cholesterol (LDL-c) is the primary aim of lipid-lowering therapies as a method of atherosclerotic cardiovascular disease risk reduction.
Jaimini Cegla, Ben Jones, Kausik K Ray, Stewart Wilson, Ferruccio De Lorenzo, Pritpal Padam, Lucy Barton, Alessia David, Shahenaz Walji   +8 more
doaj   +1 more source

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2019
BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who
S. Wiviott, I. Raz, M. Bonaca, Ofri Mosenzon, Eri Toda Kato, A. Cahn, Michael G. Silverman, Thomas A. Zelniker, J. Kuder, S. Murphy, Deepak L. Bhatt, Lawrence A Leiter, Darren K Mcguire, J. Wilding, C. Ruff, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine   +19 more
semanticscholar   +1 more source